CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Biomarker Testing for Autoimmune Rheumatic Disease

Defines coverage and limitations for laboratory biomarker testing (ANA, ENA, RF, anti-CCP, dsDNA, specific autoantibodies, and proprietary multibiomarker panels) used in diagnosis and monitoring of systemic autoimmune rheumatic diseases for BlueCross BlueShield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyBiomarker Testing for Autoimmune Rheumatic Disease

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder ANA testing for symptomatic individuals once during initial workup; request ENA panels only if ANA is abnormal with clinical correlation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

onceANA testing allowed during initial workup

up to 2Additional lifetime ANA tests if new/worse symptoms

up to 4/yrdsDNA testing for diagnosed SARD

not coveredProprietary multibiomarker panels

22Citations in excerpt

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Biomarker Testing

inv-01: Initial diagnostic testing

Covered when ALL of the following are met

ANA screening for symptomatic individuals: For individuals with signs or symptoms of an autoimmune disease, screening for disease using antinuclear antibodies (ANA) meets coverage criteria.

ANA frequency initial: Once during initial workup.

ANA additional testing: Up to two additional tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.

ENA when ANA abnormal: For individuals with an abnormal, raised ANA titer and a clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigens (ENA) panel testing of specific autoantibodies meets coverage criteria.

inv-02: Disease-specific and monitoring testing

RA biomarkers: For individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA), testing for rheumatoid factor (RF) and/or anti-CCP antibodies meets coverage criteria; once during initial workup, with up to two additional tests per lifetime if initial testing did not result in a diagnosis and symptoms persist or additional symptoms develop.

dsDNA monitoring in diagnosed SARD: For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, testing of dsDNA up to four (4) times per year meets coverage criteria.

Specific antibody testing with low/negative ANA: For individuals with a negative or low positive ANA test, the following condition specific antibody testing meets coverage criteria: a) anti-Jo-1 in a unique clinical subset of myositis; b) anti-SSA in the setting of lupus or Sjögren's syndrome.

Monitoring of disease with antinuclear antibody (ANA) testing or reporting of ANA titers does not meet coverage criteria. ANA and/or extractable nuclear antigen (ENA) testing does not meet coverage criteria for individuals without signs or symptoms suggestive of an autoimmune disorder, including testing performed during routine wellness visits or general exams without abnormal findings. Requests for testing of specific autoantibodies in the absence of a positive ANA are also not covered, except where explicitly specified elsewhere in this policy.

Serum biomarker panels and proprietary multibiomarker assays that are not described as covered elsewhere in this policy are not covered. Examples specifically listed as not meeting coverage criteria include panels titled as Seronegative Rheumatoid Arthritis Profile, management panels such as Vectra DA and PrismRA, and proprietary algorithms or index-score tests for systemic lupus erythematosus (SLE) or connective tissue disease (CTD) diagnosis/prognosis/monitoring (for example, AVISE products, aisle® DX, and Early Sjögren's Syndrome Profile). These panels lack sufficient published evidence of clinical benefit for the indicated uses described in this policy.

The source document includes numerous guideline and literature citations that support clinical context and discussion of multibiomarker tests and disease classification, but these referenced chunks do not themselves state additional coverage determinations or explicit exclusion language. They provide bibliographic support (validation studies, guideline updates, and epidemiologic references) that informed the policy statements.

Use of proprietary multibiomarker panels and algorithmic index scores (examples cited in the policy include Vectra DA, PrismRA, AVISE panels, and other named proprietary assays) for diagnosis, prognosis, or monitoring of SLE, RA, or other connective tissue diseases does not meet coverage criteria and is considered not medically necessary under this policy.

Procedure and Test Codes

Listed procedure and proprietary test codesmixed

81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, prognostic algorithm reported as a disease activity score (Proprietary test: Vectra®DA)
81599	Unlisted multianalyte assay with algorithmic analysis
86038	Antinuclear antibodies (ANA)
86039	Antinuclear antibodies (ANA); titer
86200	86200
86225	86225
86235	Sm, RNP, Sc170, J01), each antibody
86430	86430
86431	Rheumatoid factor; quantitative
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity (Proprietary test: Anti-dsDNA, High Salt/Avidity)

1–10 of 15

1/2

inv-08: dsDNA testing frequency

Allowed frequencydsDNA testing for individuals with an initial positive ANA and a diagnosis of a systemic autoimmune rheumatic disease: up to 4 times per year.

ContextIntended for monitoring individuals with a diagnosed SARD and prior positive ANA; not for routine screening in asymptomatic individuals.

Documentation noteClinical diagnosis of a systemic autoimmune rheumatic disease and prior positive ANA should be documented when dsDNA testing is requested.

Provider Actions, Documentation, and Billing Guidance

Billing Rule

Listed procedure codes and proprietary tests

Listed procedure codes and proprietary tests referenced in the policy (for provider billing and claims submission): Vectra® DA (Proprietary multi-biomarker algorithm) — Crescendo Bioscience, Inc.; CPT/HCPCS and other codes cited include but may not be exhaustive: 81490 (unlisted multianalyte assay with algorithmic analysis), 81599 (unlisted multianalyte assay), 86038 (ANA, screen), 86039 (ANA, titer), 86200, 86225, 86235 (individual antibody assays such as Sm, RNP, Scl70, Jo-1), 86430, 86431 (rheumatoid factor quantitative), 0039U (Anti-dsDNA high salt/avidity), 0062U (SLE-key® Rule Out), 0312U, 0446U, 0447U, 0521U. Procedure codes listed in policy documents are provided as a reference and may not be all-inclusive; verify current coding guidance before submission.

Vectra® DA — Crescendo Bioscience, Inc. (Proprietary test)
Common referenced codes: 81490, 81599, 86038, 86039, 86200, 86225, 86235, 86430, 86431
Proprietary/other test codes: 0039U (Anti-dsDNA High Avidity), 0062U (SLE-key® Rule Out), 0312U, 0446U, 0447U, 0521U

Definitions and Key Terms

inv-18: ANA — Antinuclear antibody

DefinitionAntinuclear antibody (ANA) — a screening assay to detect autoantibodies against intracellular antigens used in initial workup for suspected systemic autoimmune rheumatic disease.

Initial testingANA testing meets coverage criteria once during initial diagnostic workup for individuals with signs or symptoms of an autoimmune disease.

LimitationsMonitoring of disease with ANA testing or ANA titers does NOT meet coverage criteria; ANA testing for asymptomatic individuals or wellness visits does NOT meet coverage criteria.

inv-19: ENA — Extractable nuclear antigens (Sm, U1 RNP, Ro, La)

DefinitionExtractable nuclear antigens (ENA) — include Sm, U1 RNP, Ro, and La; useful for evaluating suspected connective tissue disease.

Coverage trigger

Background

Systemic autoimmune rheumatic diseases (SARDs) are heterogeneous disorders characterized by immune dysregulation and autoantibodies. ANA is commonly used as an initial screening test, and extractable nuclear antigens (ENA) and disease-specific autoantibodies support diagnosis of conditions such as systemic lupus erythematosus, Sjögren's syndrome, mixed connective tissue disease, systemic sclerosis, and idiopathic inflammatory myopathies. The policy’s literature citations and guideline references (including ACR/EULAR criteria and contemporary RA and SLE guidance) provide the clinical foundation for the coverage positions described herein.

Revision History and References

2024-05-15bibliography_update

CDC 'Lupus Basics' web page updated and cited in policy references.

2023bibliography_addition

EULAR 2022 RA management update published (Annals of the Rheumatic Diseases 2023) and cited in policy references.

2021-01-04bibliography_addition

Validation study of the adjusted multibiomarker disease activity score published and cited in policy references.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyBiomarker Testing for Autoimmune Rheumatic Disease

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder ANA testing for symptomatic individuals once during initial workup; request ENA panels only if ANA is abnormal with clinical correlation.

SourceLink

On This Page

Prior Authorization

Prior authorization not specified

This policy does not specify any prior authorization requirements. Providers should confirm member-specific benefit coverage and any plan-level prior authorization rules separately through the payer's authorization portal or member benefits.

Denial Risk

Denial triggers for inappropriate testing

Testing performed without appropriate clinical indications may be denied. Examples of denial triggers include: ANA and/or ENA testing in asymptomatic individuals, testing solely as part of a routine wellness visit or general exam without abnormal findings, ordering specific antibody testing in the absence of a positive ANA when not otherwise indicated, and use of proprietary multibiomarker panels or serum biomarker algorithm scores (e.g., Vectra® DA, AVISE panels, PrismRA) for diagnosis or monitoring when policy states they do not meet coverage criteria.

ANA and/or ENA testing for asymptomatic individuals or routine wellness exams without abnormal findings
Specific antibody testing ordered without a preceding abnormal/positive ANA when not described in indications
Proprietary serum biomarker panels/algorithm scores for diagnosis, prognosis, or monitoring when listed as not meeting coverage

Note

No authorization or denial criteria specified

The policy contains no separate authorization or formal denial criteria beyond the coverage statements provided in the Indications and Limitations sections. Operational coverage decisions should follow the clinical indications, frequency limits, and the 'does not meet coverage criteria' statements in this policy; consult member benefits and any applicable government (LCD/NCD) rules for program-specific mandates.

Documentation Required

Clinical correlation required

Clinical correlation is required: abnormal or elevated ANA titers must be interpreted in the context of the individual's signs and symptoms. ENA panel testing and specific autoantibody assays are considered covered only when there is a positive or abnormal ANA result together with clinical findings consistent with an autoimmune disorder.

ANA/ENA results require accompanying signs or symptoms of autoimmune disease for coverage
ENA/specific autoantibody testing covered when abnormal ANA plus clinical correlation is present

Documentation Required

Documentation requirements not specified

The policy does not specify additional documentation requirements beyond standard medical record documentation of signs, symptoms, diagnostic rationale, and results. Providers should retain clinical notes supporting the medical necessity of testing (e.g., history, exam findings, diagnostic impressions) and be prepared to supply records upon payer request.

ENA panel testing meets coverage criteria when there is an abnormal/raised ANA titer with clinical correlation to an appropriate autoimmune disorder.

LimitationsENA testing for individuals without symptoms or during wellness visits does NOT meet coverage criteria.

inv-20: Proprietary multibiomarker assays (e.g., Vectra DA, AVISE)

Definition / examplesProprietary multibiomarker assays — serum biomarker panel tests with proprietary algorithms (examples cited: Vectra DA, PrismRA, AVISE CTD/SLE, AVISE SLE Monitor/Prognostic, aiSLE DX, Early Sjögren’s Syndrome Profile).

Coverage stanceUse of proprietary multibiomarker panels and algorithmic index scores for diagnosis, prognosis, or monitoring of SLE, RA, or other connective tissue diseases DOES NOT MEET COVERAGE CRITERIA.

Specific management noteSerum biomarker panel testing for management of RA (e.g., Vectra DA score, PrismRA) does NOT meet coverage criteria.

inv-21: MBDA score — multibiomarker disease activity score for RA

DefinitionMultibiomarker disease activity (MBDA) score — a composite biomarker-based score (example: Vectra DA, CPT 81490) developed to measure RA disease activity and prognostic risk.

Evidence referencesMultiple validation and prognostic studies are cited assessing MBDA association with radiographic progression, remission, and discrepancies with clinical scores (see referenced literature).

CodingProprietary MBDA test (Vectra®DA) listed as CPT 81490; unlisted multianalyte assay code 81599 also referenced.

inv-22: ACR/EULAR classification criteria referenced

Referenced criteriaACR and EULAR classification criteria and guideline documents are referenced, including the 1997 ACR SLE update and the 2019 EULAR/ACR SLE classification criteria.

Use in policyThese standardized criteria and guideline documents inform diagnostic and classification context for SLE and RA within the policy's clinical rationale and references.

Examples cited1997 ACR update for SLE (Hochberg MC) and 2019 EULAR/ACR classification criteria for SLE are specifically listed in the references.

2020-06-24bibliography_addition

Study showing MBDA score can predict sustained remission in RA published and cited in policy references.

2019bibliography_addition

Multiple 2019 publications cited, including adjusted MBDA analyses and 2019 EULAR/ACR SLE classification criteria.

1997-09bibliography_additionLatest

ACR update to SLE classification criteria (Hochberg 1997) cited in policy references.